Unknown

Dataset Information

Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: A network meta-analysis.


ABSTRACT:

Background

Rituximab is an induction immunosuppressant essential for ABO-incompatible kidney transplantation (ABOi KT). However, studies on its dosing, which differs among countries and transplant centers, are lacking. Therefore, we retrospectively investigated the effectiveness of the induction dose of rituximab against patient mortality, graft failure, and adverse events.

Methods

We included the studies referring to at least 2 of eligible induction doses (200 mg, 200-500 mg, or 500 mg) of rituximab during ABOi KT and relevant outcomes such as patient survival, graft failure, and bacterial and viral infections. We performed direct and indirect network meta-analyses using Bayesian models and ranked different rituximab doses using generation mixed treatment comparison. Public

SUBMITTER: Lee HR 

PROVIDER: S-EPMC7969271 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature